Active Not RecruitingNot applicableNCT04946279

Decision Aid for the Improvement of Decision-Making in Patients With Non-small Cell Lung Cancer

This clinical trial refines and tests the effect of a decision aid in improving decision-making in patients with non-small cell lung cancer. Patients with cancer want to be informed about their diagnoses, treatment procedures and goals of treatment. They also seek active roles in decision-making. Shared decision-making (SDM) is the process of clinician and patient jointly participating in a health decision after discussing the options, benefits and harms, and considering the patient's values, preferences, and circumstances. SDM can improve patient involvement in decision making, satisfaction, health care quality, and quality of life. Decision aids can improve patient knowledge, create more realistic outcome expectations; reduce decisional conflict, distress, depression and uncertainty; and improve physician-patient communication and quality of life, compared with no decision aid. This trial's main aim is to evaluate the feasibility and efficacy of a decision aid in patients with non-small cell lung cancer.

Checked against the public recordLast updated Sep 5, 2025 · Source: ClinicalTrials.gov

StatusActive Not Recruiting
PhaseNot applicable
U.S. locations2
SponsorOHSU Knight Cancer Institute
01
Study overview

What this study is about

Purpose
Health Services Research
Study type
Interventional
Phase
Not applicable
Sponsor
OHSU Knight Cancer Institute
Interventions being studied
Other: Best Practice; Other: Informational Intervention; Other: Questionnaire Administration
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * PART I: Completed treatment for suspected or confirmed stage I-IV non-small cell lung cancer (NSCLC) * PART I: English fluency * PART II: Undergoing diagnostic work-up for suspected stage I-IV NSCLC * PART II: English fluency * PART II: \> 6-month life expectancy * PART II: Score of \> 3 on the 6-Item Screener for Cognitive Impairment

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • OHSU Knight Cancer InstitutePortland, Oregon
  • Portland VA Medical CenterPortland, Oregon

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 5, 2025. Always confirm current availability with the study team.

View original record ↗